AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma

Retrieved on: 2021-06-08 17:37:30

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma. View article details on hiswai:

Excerpt

NEW YORK – AstraZeneca's PARP inhibitor olaparib (Lynparza) failed to stave off cancer progression for six months in recurrent, IDH-mutant, ...

Article found on: www.precisiononcologynews.com